Enumeral Biomedical Holdings, Inc. (OTCQB: ENUM), a biotechnology
company focused on discovering and developing novel antibody
immunotherapies that help the immune system fight cancer and other
diseases, today announced that Enumeral will present a poster titled
“Human Tumor-Based Identification of Immune Checkpoint Targets” at the
International Cancer Immunotherapy Conference. Enumeral’s poster will
highlight recent developments in the company’s PD-1 and TIM-3 antibody
programs. The poster number is B083, and will be presented in the Empire
Ballroom at the Sheraton New York Times Square Hotel in New York City
from 4:45 pm to 6:45 pm on September 18, 2015.
In addition, Cokey Nguyen, Ph.D., Vice President of Research and
Development at Enumeral, will make a presentation on Enumeral’s drug
discovery programs at the BioPharm America 2015 conference at the Boston
Marriott Copley Place Hotel in Boston, Massachusetts at 12:00 noon on
September 17, 2015. BioPharm America is one of North America’s premier
life sciences conferences, bringing together biotech and pharma
executive from around the world to identify and pursue strategic
relationships among the participants.
About Enumeral
Enumeral is a biopharmaceutical company discovering and developing novel
antibody immunotherapies that help the immune system fight cancer and
other diseases. The Company is building a pipeline focused on
next-generation checkpoint modulators, with initial targets including
PD-1, TIM-3, LAG-3, OX40, and VISTA. In developing these agents,
Enumeral’s researchers apply a proprietary immune profiling technology
platform that measures functioning of the human immune system at the
level of individual cells, providing key insights for candidate
selection and validation. For more information on Enumeral, please visit www.enumeral.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150911005099/en/
Copyright Business Wire 2015